CordenPharma, a contract development and manufacturing organization of drug substances and drug products, is investing EUR 3.7 million ($4.3 million) in the manufacturing site infrastructure of its small-molecule manufacturing facility in Liestal, Switzerland.

The investment will include an expansion of the square footage dedicated to small molecule, peptide, and carbohydrate development services. In addition, an investment of approximately EUR 2 million ($2.3 million) in new automated development and optimization equipment is being realized to facilitate development services and an upgrading and expansion of analytical equipment.

A further feature of the facility investment is to expand and refurbish the current purification capabilities as well as the construction of a new mini-plant.

CordenPharma says the total investment will allow the Switzerland site to run an increasing number of early-phase projects in parallel to both support its own pipeline development as well as that of other facilities within the integrated CordenPharma network of manufacturing facilities across Europe and the US.

Source: CordenPharma